Effects of anti-Inflammatory-antioxidant-rich diet and co-supplemented synbiotics intervention in patients with progressive forms of multiple sclerosis: a single-center, single-blind randomized clinical trial.
Study Goal
The researchers aimed to investigate the effects of a synbiotics capsule combined with an anti-inflammatory-antioxidant-rich diet on intestinal inflammation and clinical manifestations in patients with progressive forms of Multiple Sclerosis (MS).
Results Summary
The intervention significantly reduced faecal calprotectin levels (a marker of intestinal inflammation) and improved clinical manifestations in progressive MS patients. The results suggest that synbiotics and an antioxidant-rich diet can mitigate inflammation and enhance clinical outcomes.
Population
Seventy patients with progressive forms of MS (primary-progressive, secondary-progressive, and progressive-relapsing).
Effective Dosage
Daily synbiotics capsule plus anti-inflammatory-antioxidant-rich diet (specific dosage not detailed).
Duration
Four months.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
daily synbiotics capsule plus anti-inflammatory-antioxidant rich diet | decrease | Faecal calprotectin level | patients with progressive forms of MS | 110.5 ± 75.9-44.7 ± 49.3 ɥg/g | significantly reduced | #1 |
daily synbiotics capsule plus anti-inflammatory-antioxidant rich diet | decrease | Impact of Vision Impairment (IVI) | patients with progressive forms of MS | 28.5 ± 19.5-19.8 ± 16.1 | significantly reduced | #2 |
daily synbiotics capsule plus anti-inflammatory-antioxidant rich diet | decrease | Gastrointestinal Symptom Rating Scale (GSRS) | patients with progressive forms of MS | 1.8 ± 0.5-1.5 ± 0.4 | significantly reduced | #3 |
daily synbiotics capsule plus anti-inflammatory-antioxidant rich diet | decrease | body weight | patients with progressive forms of MS | 78.5 ± 14.5-76.8 ± 14.1 kg | significantly reduced | #4 |
daily synbiotics capsule plus anti-inflammatory-antioxidant rich diet | decrease | body mass index | patients with progressive forms of MS | 28.5 ± 4.5-27.9 ± 4.4 kg/m2 | significantly reduced | #5 |
daily synbiotics capsule plus anti-inflammatory-antioxidant rich diet | decrease | waist circumference | patients with progressive forms of MS | 98.5 ± 11.5-96.8 ± 11.1 cm | significantly reduced | #6 |
daily synbiotics capsule plus anti-inflammatory-antioxidant rich diet | decrease | fat mass | patients with progressive forms of MS | 30.1 ± 9.1-28.8 ± 8.8% | significantly reduced | #7 |
daily synbiotics capsule plus anti-inflammatory-antioxidant rich diet | increase | fat-free mass | patients with progressive forms of MS | 69.9 ± 9.1-71.2 ± 8.8% | significantly increased | #8 |
Synbiotics supplementation and adherence to an anti-inflammatory-antioxidant-rich diet | decrease | intestinal inflammation | progressive forms of MS | - | reduced | #9 |
Synbiotics supplementation and adherence to an anti-inflammatory-antioxidant-rich diet | increase | clinical manifestations | progressive forms of MS | - | improved | #10 |
BACKGROUND: Current evidence has demonstrated that patients with Multiple Sclerosis (MS) have dysbiotic gut microbiomes, and anti-inflammatory nutritional interventions can normalize this status. Therefore, we aimed to investigate the effects of dietary intervention in patients with progressive forms of MS. METHODS: Seventy patients with three forms of progressive MS (primary-progressive, secondary-progressive, and progressive-relapsing) were randomly assigned into intervention (daily synbiotics capsule plus anti-inflammatory-antioxidant rich diet) or control (placebo capsule plus dietary recommendations) groups for four months. Faecal calprotectin level, Impact of Vision Impairment (IVI), Gastrointestinal Symptom Rating Scale (GSRS), and anthropometric measurements were evaluated at baseline and trial cessation. Analysis of covariance was conducted and adjusted for age, gender, education level, family history & duration of MS, type of progressive MS, type of main drug, and physical activity. RESULTS: Sixty-nine participants were included in the final analysis (n of intervention = 34; n of control = 35). Synbiotics and dietary intervention significantly reduced Faecal calprotectin level after six months (110.5 ± 75.9-44.7 ± 49.3 ɥg/g, CONCLUSION: Synbiotics supplementation and adherence to an anti-inflammatory-antioxidant-rich diet reduced intestinal inflammation and improved clinical manifestations in progressive forms of MS.